title: ABO blood groups are not associated with treatment response and prognosis in patients with local advanced non- small cell lung cancer.
abstract: BACKGROUND
  Lung cancer is the leading cause of cancer death, late diagnosis being the main obstacle to improving the outcomes with stage at diagnosis as an important prognostic factor. Relationships between ABO blood groups and risk of benign or malignant diseases have been observed and in this study, we aimed to investigate whether they might affect prognosis and response to chemoradiotherapy in patients with local advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Eighty-one patients with non-metastatic local advanced NSCLC were included in the study. ABO blood groups were A in 45 (55.6%), B in 7 (8.6%), AB in 8 (9.9%), and O in 21 (25.9%) patients. The patients were also divided two groups according to blood group A (45 patients) and non-A (B, AB and O; 36 patients). Response to chemoradiotherapy was complete remission in 10 (12.3%), disease regression in 42 (51.9%), stable disease in 12 (14.8%), and disease progression in 17 (21.0%) patients.
  
  
  RESULTS
  There was no significant difference among ABO blood group categories or between patients with A blood group and those with non-A blood group in terms of responses to chemoradiotherapy (p>0.05). There were also no significant differences regarding overall and disease-free survival rates.
  
  
  CONCLUSIONS
  The ABO blood group system has no significant effect on prognosis and response to chemoradiotherapy in patients with non-metastatic NSCLC.
authors.affiliation: Department of Radiation Oncology, Kayseri Education and Research Hospital, Kayseri, Turkey. dilekunaldr@gmail.com
authors.forename: Dilek
authors.initials: D
authors.lastname: Unal
authors.forename: Celalettin
authors.initials: C
authors.lastname: Eroglu
authors.forename: Neslihan
authors.initials: N
authors.lastname: Kurtul
authors.forename: Arzu
authors.initials: A
authors.lastname: Oguz
authors.forename: Arzu
authors.initials: A
authors.lastname: Tasdemir
authors.forename: Bunyamin
authors.initials: B
authors.lastname: Kaplan
mesh_terms: D000017:ABO Blood-Group System / Q000378:metabolism*; D000230:Adenocarcinoma / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018196:Carcinoma, Adenosquamous / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000401:mortality* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000401:mortality / Q000628:therapy; D059248:Chemoradiotherapy / Q000401:mortality*; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000401:mortality* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D000017:ABO Blood-Group System; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin